# Evaluation of the Effects of Cannabidiol (CBD) Compared to Delta-9-Tetrahydrocannabinol (THC) and Alprazolam

> **NCT03398083** · PHASE1 · COMPLETED · sponsor: **National Institute on Drug Abuse (NIDA)** · enrollment: 42 (actual)

## Conditions studied

- Cannabis Use Disorder

## Interventions

- **DRUG:** THC
- **DRUG:** Alprazolam
- **DRUG:** Placebo oral capsule
- **DRUG:** CBD

## Key facts

- **NCT ID:** NCT03398083
- **Lead sponsor:** National Institute on Drug Abuse (NIDA)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-04
- **Primary completion:** 2018-05-30
- **Final completion:** 2018-05-30
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2018-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03398083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03398083, "Evaluation of the Effects of Cannabidiol (CBD) Compared to Delta-9-Tetrahydrocannabinol (THC) and Alprazolam". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03398083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*